Scholarlink

<p>We established and characterized a novel human sinonasal adenosquamous carcinoma (ASC) cell line, TC717, derived from a 64-year-old, never-smoking woman. The patient received neoadjuvant chemotherapy followed by total maxillectomy but succumbed to disease 6&#xa0;months after therapy initiation. TC717 recapitulated the histologic and immunohistochemical hallmarks of ASC, including squamous differentiation (p40 positivity) and mucin production. The cells displayed a stable doubling time of ~ 27&#xa0;h. WES revealed a high TMB in both the primary tumor tissue (43.0 mut/Mb) and the TC717 cell line (34.0 mut/Mb), and pathogenic <i>TP53</i> c.614A &gt; G and <i>BRAF</i> c.1574&#xa0;T &gt; C variants, neither previously reported in ASC. TC717 provides a valuable preclinical platform for investigating sinonasal ASC biology and for evaluating genotype-directed therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Establishment and characterization of a novel sinonasal adenosquamous carcinoma cell line, TC717, with a high tumor mutational burden

  • 期刊论文

  • 发表日期：

    2026年2月24日

查看全文
  • Ryosuke Kuga,
  • Takeo Yamamoto,
  • Takeshi Iwasaki,
  • Midori Taniguchi,
  • Tomomi Manako,
  • Hidetaka Yamamoto,
  • Yoshinao Oda

摘要

We established and characterized a novel human sinonasal adenosquamous carcinoma (ASC) cell line, TC717, derived from a 64-year-old, never-smoking woman. The patient received neoadjuvant chemotherapy followed by total maxillectomy but succumbed to disease 6 months after therapy initiation. TC717 recapitulated the histologic and immunohistochemical hallmarks of ASC, including squamous differentiation (p40 positivity) and mucin production. The cells displayed a stable doubling time of ~ 27 h. WES revealed a high TMB in both the primary tumor tissue (43.0 mut/Mb) and the TC717 cell line (34.0 mut/Mb), and pathogenic TP53 c.614A > G and BRAF c.1574 T > C variants, neither previously reported in ASC. TC717 provides a valuable preclinical platform for investigating sinonasal ASC biology and for evaluating genotype-directed therapies.